Keyword: Medicare

New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.

Jazz, Lundbeck and Alexion inked settlements over allegations their contributions to patient charities were designed to boost sales.

Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.

A new ad campaign from the pharma industry's trade group weighs in on proposed changes to Medicare.

Amgen declared the launch of migraine drug Aimovig an unqualified success, but analysts weren't quite ready to buy in to the euphoria.

Pharma has come under political pressure in Washington, D.C., and lobby spending figures indicate the industry is taking the threat seriously.

After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous."

Pharma suffered a blow in the Senate's budget deal, but how much will drugmakers really lose? Not a lot, on average, but some will take a bigger hit.